InMed Pharmaceuticals Inc
NASDAQ:INM
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| CA |
|
InMed Pharmaceuticals Inc
NASDAQ:INM
|
2.2m USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
939.9B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
587.8B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
256.9B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
224.3B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
234.4B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
288.2B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
153.1B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.5B USD |
Loading...
|
Market Distribution
| Min | -10 058.3% |
| 30th Percentile | 20.4% |
| Median | 33.6% |
| 70th Percentile | 50.5% |
| Max | 717.4% |
Other Profitability Ratios
InMed Pharmaceuticals Inc
Glance View
InMed Pharmaceuticals, Inc. engages in the provision of biopharmaceutical research. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2001-06-21. The firm is developing a pipeline of prescription-based products targeting treatments for diseases with unmet medical needs as well as developing manufacturing technologies. The company is specializing in the research and development of cannabinoid-based therapies and a system for the manufacturing of pharmaceutical-grade cannabinoids. The company is also developing an integrated biosynthesis-based manufacturing approach, called IntegraSyn, for synthesizing pharmaceutical-grade cannabinoids, for potential use in product candidates. The firm's two product candidates include INM-755 and INM-088. INM-755 is developed as a topical skin cream formulation containing cannabinol (CBN) for the treatment of symptoms related to Epidermolysis Bullosa (EB). INM-088 provides direct neuroprotection and reduce intraocular pressure in the eye.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for InMed Pharmaceuticals Inc is 29.7%, which is below its 3-year median of 31.4%.
Over the last 3 years, InMed Pharmaceuticals Inc’s Gross Margin has increased from 4.3% to 29.7%. During this period, it reached a low of 3.4% on Mar 31, 2023 and a high of 40.6% on Sep 30, 2023.
